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The impact of early donor cell chimerism on outcomes of T cellereplete reduced-intensity conditioning (RIC)
hematopoietic stem cell transplantation (HSCT) is ill deﬁned. We evaluated day 30 (D30) and 100 (D100) total
donor cell chimerism after RIC HSCT undertaken between 2002 and 2010 at our institution, excluding
patients who died or relapsed before D30. When available, donor T cell chimerism was also assessed. The
primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS),
relapse, and nonrelapse mortality (NRM). We evaluated 688 patients with hematologic malignancies (48%
myeloid and 52% lymphoid) and a median age of 57 years (range, 18 to 74) undergoing RIC HSCT with T celle
replete donor grafts (97% peripheral blood; 92% HLA-matched), with a median follow-up of 58.2 months
(range, 12.6 to 120.7). In multivariable analysis, total donor cell and T cell chimerism at D30 and D100 each
predicted RIC HSCT outcomes, with D100 total donor cell chimerism most predictive. D100 total donor cell
chimerism <90% was associated with increased relapse (hazard ratio [HR], 2.54; 95% conﬁdence interval [CI],
1.83 to 3.51; P < .0001), impaired PFS (HR, 2.01; 95% CI, 1.53 to 2.65; P < .0001), and worse OS (HR, 1.50; 95%
CI, 1.11 to 2.04, P ¼ .009), but not with NRM (HR, .76; 95% CI, .44 to 2.27; P ¼ .33). There was no additional
utility of incorporating sustained D30 to D100 total donor cell chimerism or T cell chimerism. Low donor
chimerism early after RIC HSCT is an independent risk factor for relapse and impaired survival. Donor
chimerism assessment early after RIC HSCT can prognosticate for long-term outcomes and help identify
high-risk patient cohorts who may beneﬁt from additional therapeutic interventions.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Reduced-intensity conditioning (RIC) allogeneic hemato-
poietic stem cell transplantation (HSCT) is critically depen-
dent on the immunologic graft-versus-tumor response for its
curative potential. In RIC HSCT, T cell depletion (TCD) with
in vivo antithymocyte globulinebased conditioning appears
associated with increased relapse and impaired survival [1].
In T cellereplete RIC HSCT, early donor engraftment and
immune reconstitution kinetics remain variable and may
predict the likelihood of graft-versus-tumor response and
long-term survival.edgments on page 1521.
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14.05.025The prognostic impact of donor chimerism early after
T cellereplete RIC HSCT is ill deﬁned. Data on total donor cell
chimerism are especially scanty and discordant, as most
studies have focused on donor T cell chimerism. Two small
studies found no association of low total donor cell chime-
rism with outcomes [2,3], whereas other small studies, with
varying chimerism thresholds and assessment time points,
described an association with 4-week relapse risk [4] or
impaired survival [5,6]. Several small studies have also
described an association of donor T cell chimerism with
impaired RIC HSCT outcomes [7-10]. However, in the largest
study (n ¼ 322), lack of full donor T cell chimerism was a
predictor of relapse but not of progression-free survival (PFS)
[11]. Additional limitations are that studies often included
recipients of TCD (where increased mixed chimerism has
been reported) and did not fully adjust for disease relapse
likelihood (eg, Disease Risk Index [DRI] [12]) or otherTransplantation.
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count [ALC] [13,14] or WBC risk score [15]), which can also
affect HSCT outcomes. The comparative utility of total donor
cell versus T cell chimerism is also ill deﬁned. Early donor cell
chimerism has, therefore, not been incorporated into RIC
HSCT prognostic models.
We undertook a retrospective analysis of adult T celle
replete RIC HSCT performed at our institution between 2002
and 2010 to comprehensively assess the impact of early
donor chimerism on overall survival (OS). We sought to
evaluate the following: (1) the impact of day 30 (D30) and
day 100 (D100) total donor cell chimerism, (2) the additional
utility of “sustained” total donor cell chimerism between
D30 and D100, and (3) the additional utility of D30 and D100
donor T cell chimerism.
MATERIALS AND METHODS
Patients
At our institution, RIC HSCT is offered to adults with advanced and/or
aggressive hematologic malignancies unsuitable for myeloablative trans-
plantation because of disease, age, or comorbidities. Pretransplantation
eligibility includes Eastern Cooperative Oncology Group performance status
2, adequate organ function (pulmonary, cardiac, renal, hepatic), and no
active uncontrolled infections. Recipients are routinely consented to insti-
tutional review boardeapproved data collection.
T cellereplete RIC HSCT in 688 adult hematologic malignancy patients
between 2002 and 2010 are included in the analysis. Patients who relapsed
or died before the dates of D30 or D100 chimerism were excluded from the
respective D30 or D100 analysis.
HSCT Regimen
Recipients received RIC ﬂudarabine (30 mg/m2  4 days) and busulfan
(1.6 mg/kg i.v. once or twice daily  4 days) followed by T cellereplete bone
marrow or peripheral blood stem cell (PBSC) grafts. Graft-versus-host dis-
ease (GVHD) prophylaxis routinely comprised methotrexate on days 1, 3, 6,
11, with tacrolimus sirolimus starting day3 and tapered throughweeks
9 to 26 in the absence of GVHD. All patients received 12 months of infection
prophylaxis, surveillance, and preemptive therapy. Donor lymphocyte in-
fusions were at the discretion of the treating physician, but in the absence of
relapse, they were used only in 2 patients to treat falling donor chimerism.
Chimerism Analysis
Post-transplantation D30 (range, 20 to 50) and D100 (range, 80 to 120)
chimerism were determined using recipient peripheral blood (PB) or bone
marrow samples collected in EDTA. Total donor cell chimerism was per-
formed on buffy coat leukocytes. T cell chimerism was on Ficoll Hypa-
queeseparated lymphocytes fromwhich puriﬁed CD3þ T cells were isolated
using immunomagnetic beads (Stem Cell Technologies Inc., Vancouver,
Canada). Pretransplantation PB samples were used to determine the donor
and recipient genotypes based on 9 CODIS short tandem repeat loci using
the Applied Biosystems Proﬁler Plus kit with the ABI 3130 capillary genetic
analyzer (Thermo Fisher Scientiﬁc Inc., Waltham, MA) to determine the al-
leles at each locus. Informative alleles unique to either donor or recipient
were used to calculate percent donor chimerism at each locus, using the
median peak intensity of amplicons attributable to donor divided by the
sum of all amplicons at that locus. In cases where there were only unique
recipient amplicons, the percent donor chimerismwas calculated as 100 less
the percent recipient chimerism. The 95% conﬁdence interval for chimerism
was 5%.
Statistical Methods
Patient baseline characteristics were reported descriptively. OS and PFS
were calculated with the Kaplan-Meier method. OS, PFS, cumulative inci-
dence of relapse, and nonrelapse mortality (NRM) were deﬁned previously
[12,15]. The log-rank test was used for comparisons of Kaplan-Meier curves.
The difference between cumulative incidence curves in the presence of
a competing risk was tested with the Gray method [16]. The cumulative
incidence of GVHD was also calculated in the competing risks framework,
reﬂecting death or relapse without developing GVHD as a competing event.
Potential prognostic factors for OS, PFS, relapse, and NRMwere examined in
the proportional hazards model, as well as in the competing risks regression
model [17]. The models included pretransplantation factors (age, diagnosis,
DRI, donor-recipient HLA-match, sex-match, ABO-match, cytomegalovirus
serostatus, prior allotransplantation), transplantation factors (year, condi-
tioning intensity, sirolimus use), and post-transplantation factors (WBCrisk score based on 1- and 3-month WBC values, 1- and 3-month ALC).
(Supplementary Table 1). The proportional hazards assumption for each
variable of interest was tested and interaction terms were examined. The
linearity assumption for continuous variables was examined by the use of
restricted cubic spline estimates of the relationship between the continuous
variable and log relative hazard [18], and the cutoff points of these variables
were determined by the change of the log relative hazards. For total donor
cell and T cell chimerism, this approach is supplemented with calculation of
hazard ratios of PFS by intervals of 10 and 20, along with the consideration of
the number of events in each interval. From these approaches, the proposed
cutoff value for total donor cell chimerismwas<90% (low) versus90%, and
<70% (low) versus 70% for donor T cell chimerism (Figure 1C,D). Although
the linearity assumption for total donor cell and T cell chimerism values was
not violated, we propose these cutoff values to facilitate the practical use of
chimerism data. We compared predictive capacities via the concordance
index (C-index) [19,20]. All P values are 2-sided with a signiﬁcance level of
.05. All calculations were performed with SAS 9.3 (SAS Institute, Cary, NC),
and R 2.14.1 (the Comprehensive R Archive Network project).
RESULTS
Patients
Characteristics of the 688 patients are shown in Table 1.
Diagnoses were 52% lymphoid and 48% myeloid malig-
nancies. Seventeen percent had undergone prior allogeneic
HSCT. Donors were 64% unrelated, 92% 8/8 HLA-matched,
and 97% provided PBSC grafts. Median recipient age was
57 years (range, 18 to 74), with median donor age of 39 years
(range, 12 to 73). Median follow-up in survivors was
58.2 months (range, 12.6 to 120.7).
Total Donor Cell Chimerism
D30 and D100 total donor chimerism data were available
for 688 and 530 patients, respectively, as 146 patients died or
relapsed before D100 and 12 had missing D100 chimerism.
Low (<90%) total donor cell chimerism occurred in 26% of the
cohort at D30 and in 21% at D100 (Figure 1A). Fourteen
percent had persistent low total donor cell chimerism at both
D30 and D100, identical for lymphoid and myeloid disease.
Total Donor Cell Chimerism and HSCT Outcomes
In univariable analyses, total donor cell chimerism was
associated with better outcomes (Table 2). Low D30 total
donor cell chimerism had higher 2- and 5-year relapse rates
of 60% and 67%, compared with 44% and 47%, respectively
(P < .0001) and worse 2- and 5-year PFS of 31% and 26%,
compared with 47% and 36%, respectively (P ¼ .0001). Five-
year NRM was 10% compared with 17% (P ¼ .047), and
5-year OS was 41% compared with 45% (P ¼ .046).
Low D100 total donor cell chimerism had higher 2- and
5-year relapse rates of 53% and 60%, compared with 30%
and 33%, respectively (P < .0001), worse 2- and 5-year PFS of
37% and 27%, compared with 59% and 48%, respectively
(P < .0001), and worse 5-year OS of 44%, compared with 56%
(P ¼ .0007) (Figure 2A-C). The 1-year incidence of chronic
GVHD was lower at 46%, compared with 58% (P ¼ .005). The
5-year NRM did not differ (Figure 2C). The impact on
lymphoid and myeloid disease was similar (Table 2,
Supplementary Figure 1A-D).
In multivariable models, total donor chimerism was
independently associated with better outcomes. Low D30
total donor cell chimerism was associated with higher
relapse (HR, 1.66; P < .0001) and impaired PFS (HR, 1.41;
P ¼ .0013) but not with OS (HR, 1.08; P ¼ .50) (Table 3). Low
D100 total donor cell chimerism was associated with higher
relapse (P < .0001) and impaired PFS (HR, 2.01; P < .0001)
and OS (HR, 1.50; P ¼ .009) but not with NRM (HR, .76;
P ¼ .33) (Table 3, Supplementary Table 1). Myeloid or
lymphoid diagnosis did not affect the results of the analysis.
Figure 1. (A) Distribution of D30 and D100 total donor cell chimerism. Columns represent percent of patients within each percent chimerism category. (B) Distri-
bution of D30 and D100 donor T cell chimerism. Columns represent percent of patients within each percent chimerism category. (C) Change in log hazard ratio of PFS
for D30 and D100 total donor cell chimerism cutoffs. (D) Change in log hazard ratio of PFS for D30 and D100 donor T cell chimerism cutoffs.
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total donor cell chimerism for 530 patients who were alive
and relapse free at D100, using the C-index, the probability of
concordance between predicted and observed survival among
all usable pairs. The multivariable C-index of low versus90%
D30 total donor cell chimerism for PFS and OS was .626 and
.631, respectively, whereas at D100 it was higher, at .646 and
.644, respectively. C-index utilizing chimerism as a continuous
variable also indicated that D100 total donor cell chimerism
had greater predictive capacity (data not shown).
Sustained D30 to D100 Total Donor Chimerism
Of the 530 patients alive and relapse free at D100, few
experienced a change of total donor cell chimerism category
between D30 and D100: 50 (9.4%) had a rise from a low D30
to90% D100 chimerism, and 36 (6.7%) had a fall from90%
D30 to a low D100 chimerism. PFS and OS at 5 years were
determined by D100 chimerism and did not differ signiﬁ-
cantly between those remaining within their chimerism
categories between D30 and D100 versus those moving be-
tween categories (Figure 2D, and data not shown). We also
compared the predictive capacity of D100 versus 4 categories
of D30 to D100 total donor chimerism (ie, <90% and <90%
[stable low], <90% and 90% [rising], 90% and <90% [fall-
ing], and 90% and 90% [stable high]). The C-index of low
versus 90% D100 total donor cell chimerism was .646 and
.644 for PFS and OS, respectively, whereas for D30 and D100
it was .646 and .646, respectively, indicating negligible utility
of incorporating sustained D30 to D100 total cell chimerism.
Donor T Cell Chimerism
D30 and D100 donor T cell chimerism were available for
293 and 337 patients, respectively. Importantly, there wereno differences in 5-year PFS and OS for patients with avail-
able versus missing D30 or D100 T cell chimerism (P ¼ not
signiﬁcant, data not shown). Low (<70%) donor T cell
chimerism occurred in 55% at D30 and 37% at D100
(Figure 1B). There was limited correlation between donor
T cell and total donor cell chimerism, with D30 and D100
Spearman correlation coefﬁcients of .57 and .63, respectively.
Donor T Cell Chimerism and Outcomes
In univariable analyses, early donor T cell chimerism was
associated with better outcomes. Low D30 donor T cell
chimerism had a higher 5-year relapse rate of 59%, compared
with 40% (P¼ .0016), and worse 5-year PFS of 30%, compared
with 39% (P ¼ .014). NRM at 5 years was 11%, compared with
21% (P ¼ .12), and 5-year OS was 41%, compared with 45%
(P ¼ .33).
Low D100 donor T cell chimerism had a higher 5-year
relapse rate of 52%, compared with 30% (P < .0001), and
impaired 5-year PFS of 38%, compared with 48% (P ¼ .004).
NRM at 5 years was 10%, compared with 22% (P ¼ .078), and
5-year OS was 55%, compared with 54% (P ¼ .34).
In multivariable models, donor T cell chimerism was also
associated independently with better outcomes. Low
D100 T cell chimerism was associated with higher relapse
(P ¼ .0003) and impaired PFS (P ¼ .01), but not with OS
(P ¼ .58). Myeloid or lymphoid diagnosis did not affect the
results of the analysis (data not shown).
We evaluated the predictive capacity of D100 total donor
versus T cell chimerism for patients with both data available
using the C-index. The C-index of low versus90% D100 total
donor cell chimerism for PFS and OS was .646 and .662,
respectively, but for D100, T cell chimerismwas lower at .633
and .652, respectively. We also evaluated the predictive
Table 1
Baseline Patient, Disease, and Donor Characteristics of the T CelleReplete
RIC HSCT Cohort
Characteristic N %
Total 688 100
Patient age, median (range), yr 57 (18-74)
Patient sex
Male 437 63.5
Female 251 36.5
Donor age, median (range), yr 39 (12-73)
Donor sex
Male 400 58.1
Female 288 41.9
Patient-donor sex match
Female-female 117 17
Female-male 134 19.5
Male-female 171 24.9
Male-male 266 38.7
Diagnosis
AML 193 28.1
CLL, SLL, PLL 113 16.4
CML 22 3.2
Hodgkin disease 52 7.6
MM/PCD 32 4.7
ALL 19 2.8
MDS 94 13.7
MPD 21 3.1
Mixed MDS/MPD 2 .3
NHL 140 20.3
Donor HLA-matching
8/8 Matched unrelated 394 57.3
8/8 Matched related 242 35.2
7/8 Mismatch unrelated 49 7.1
7/8 Mismatch related 3 .4
Stem cell source
Bone marrow 20 2.9
Peripheral blood 668 97.1
Disease risk index
Low 159 23.1
Intermediate 362 52.6
High 155 22.5
Very high 12 1.7
Patient-donor CMV status 230 33.4
Negative 230 33.4
Any positive 458 66.6
Acute GVHD prophylaxis
CNI þ sirolimus based 483 70.2
CNI þ non-Sirolimus based 193 27.9
Other 12 1.7
Prior allogeneic transplantation 114 16.6
Conditioning regimen intensity
Bu1 559 81.3
Bu2 129 18.8
Year of transplantation, range 2002-2010
AML indicates acute myeloid leukemia; CLL/SLL/PLL, chronic lymphocytic
leukemia/small lymphocytic leukemia/pro-lymphocytic leukemia; CML,
chronic myeloid leukemia; MM/PCD, multiple myeloma/plasma cell
dyscrasia; ALL, acute lymphoid leukemia; MDS, myelodysplastic syn-
dromes; MPD, myeloproliferative diseases; NHL, non-Hodgkin lymphoma;
CMV, cytomegalovirus; CNI, calcineurin inhibitor; Bu1, once-daily busulfan
RIC; Bu2, twice-daily busulfan RIC.
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for the same set of patients, and the C-index was .649 and .66
for PFS and OS, respectively, indicating negligible additional
utility of incorporating donor T cell chimerism.DISCUSSION
Hematologic malignancy relapse after T cellereplete RIC
HSCT remains themajor hazard and determinant of long-term
survival. One predictor of relapse is pretransplantation disease
risk, but the identiﬁcation of additional potentially modiﬁable
predictors early in the post-transplantation period, before theonset of morphologic relapse, will be important for devel-
oping potential intervention strategies.
Total and T subset donor cell chimerism early after RIC
HSCTare routinemeasures of engraftment kinetics, andmost
studies have focused on T subset chimerism as a measure of
immunologic graft-versus-tumor capacity. However, results
thus far have been mixed. For instance, the largest prior
study (n ¼ 322) in this context documented the impact of
T cell chimerism on relapse but not on survival [11]. Further,
chimerism threshold cutoffs and time points and the utility
of total versus T cell chimerism have not been systematically
assessed. The survival impact of donor chimerism early after
RIC HSCT remains ill deﬁned. Early donor chimerism is,
therefore, not usually included in prognostic models of RIC
HSCT outcome.
We undertook a systematic analysis of adult T celle
replete RIC HSCT performed at our institution from 2002 to
2010 to better address this important issue. All 688 hemato-
logic malignancy patients with available chimerism data
were included. The large cohort is homogeneouswith regards
to therapy: busulfan/ﬂudarabine RIC without in vivo TCD and
predominantly PBSC grafts with methotrexate, tacrolimus, 
sirolimus GVHD prophylaxis. We evaluated D30 and D100
total donor cell chimerism, and in subset analysis, T cell
chimerism, with a primary endpoint of OS. The goal was to
determine chimerism threshold cutoffs, the survival impact
of D30 and D100 total donor cell chimerism, the additional
utility of sustained D30 to D100 total donor cell chimerism,
and the additional utility of donor T cell chimerism.
We identiﬁed total donor cell and T cell chimerism cutoffs
of 90% and 70%, respectively, based on change of log relative
hazard ratio of PFS. We found that>70% of patients achieved
total donor cell chimerism of 90% at D30 and D100. The
distribution of donor T cell chimerism was more broadly
spread, from<50% to 100%, particularly at D30. Furthermore,
patientswith90%donor Tcell chimerismwere not better off
comparedwith thosewith 70% to 90% donor Tcell chimerism.
Early donor chimerism was an independent prognostic
predictor of long-term outcomes in T cellereplete RIC HSCT.
Low D100 total donor cell chimerism was associated with
increased relapse and impaired PFS and OS. The magnitude
of the C-index of D100 total donor cell chimerism may
appear modest (.644), likely a reﬂection of heterogeneous
disease, patient, and transplantation characteristics in
allogeneic HSCT studies. We note that the predictive ca-
pacity for OS reported here is in the range of that for the
widely used HCT CI (.624) and the recently proposed DRI
(.643) [21,22].
D100 provided greater predictive capacity than D30
chimerism, which, however, remains important, as many
patients died or relapsed before D100. Indeed, D30 may
represent a timely point for therapeutic interventions to
forestall early relapse (eg, immunosuppression taper, donor
lymphocyte infusions, or novel therapies) as the apparent
lower cumulative incidence of NRM in the low D30 chime-
rism cohort is largely due to a higher number of relapses in
this group.We refer those interested to a detailed description
of competing risks data analysis per Gray (1988) and Kalb-
ﬂeisch and Prentice (2002) [16,23]. Incorporating sustained
D30 to D100 total donor cell chimerism did not add predic-
tive capacity. In subset analysis, donor T cell chimerism was
independently associated with relapse and PFS, but not with
OS. Donor T cell chimerism alone or in combination did not
add predictive capacity above that of D100 total donor cell
chimerism alone.
Table 2
Univariable Outcome by D30 and D100 Total Donor Cell Chimerism Level
Outcome D30 Chimerism* D100 Chimerismy
<90 90 P Value <90 90 P Value
N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI)
All Patients 5-yr OS 182 41 (34-48) 506 45 (40-50) .046 110 44 (36-55) 420 56 (51-61) .0007
5-yr PFS 26 (20-33) 36 (31-41) .0001 27 (18-36) 48 (42-53) <.0001
5-yr CI of NRM 10 (6-15) 17 (13-21) .047 14 (8-21) 19 (15-23) .58
5-yr CI of Relapse 67 (56-70) 47 (43-52) <.0001 60 (49-68) 33 (29-38) <.0001
D180 CI of Gr 2-4 aGVHD 22 (16-28) 21 (17-24) .85
1-yr CI of cGVHD 46 (36-55) 58 (53-62) .005
Myeloid 5-yr OS 99 33 (24-43) 233 39 (32-45) .28 58 39 (26-52) 182 53 (45-60) .012
5-yr PFS 25 (17-34) 33 (27-40) .019 23 (12-35) 49 (41-56) <.0001
5-yr CI of NRM 9 (5-16) 18 (13-23) .02 11 (4-21) 21 (15-28) .15
5-yr CI of Relapse 66 (55-74) 49 (42-56) .0008 66 (51-78) 30 (24-37) <.0001
D180 CI of Gr 2-4 aGVHD 17 (10-25) 18 (13-23) .87
1-yr CI of cGVHD 41 (28-54) 54 (46-61) .025
Lymphoid 5-yr OS 83 50 (38-61) 273 51 (44-57) .12 52 50 (35-63) 238 59 (52-66) .029
5-yr PFS 28 (19-38) 39 (33-46) .004 30 (18-44) 47 (40-54) .0025
5-yr CI of NRM 12 (6-20) 16 (11-21) .61 17 (8-29) 17 (12-23) .50
5-yr CI of Relapse 61 (49-70) 45 (39-52) .003 53 (38-66) 36 (29-42) .014
D180 CI of Gr 2-4 aGVHD 28 (19-38) 23 (19-29) .90
1-yr CI of cGVHD 50 (36-63) 61 (54-66) .15
Gr indicates grade; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
* Patients who relapsed or died before the date of D30 chimerism are excluded.
y Patients who relapsed or died before the date of D100 chimerism are excluded.
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lyses, including potential selection bias, and questions re-
garding the generalizability of single-center analyses. The
strengths of this study, namely a large homogeneous cohortFigure 2. (A) OS by D100 total donor cell chimerism level (<90% versus 90%). (B) PFS
NRM by D100 total donor cell chimerism level (<90% versus 90%). (D) PFS by D30 t
versus 90%).of adult hematologic malignancy patients treated at a single
center by the same physicians over an extended period with
uniform T cellereplete RIC, predominantly PBSC grafts,
and standard-of care methotrexate/tacrolimus-based GVHDby D100 total donor cell chimerism level (<90% versus 90%). (C) Relapse and
o D100 sustained versus nonsustained total donor cell chimerism levels (<90%
Table 3
Summary of Multivariable Cox models for OS and PFS and Competing Risks Regression Models for NRM and Relapse
D30 Total Donor Cell Chimerism: <90 versus 90 D100 Total Donor Cell Chimerism: <90 versus 90
HR 95% CI P Value HR 95% CI P Value
OS 1.08 .86 1.36 .50 1.50 1.11 2.04 .009
PFS 1.41 1.14 1.74 .0013 2.01 1.53 2.65 <.0001
NRM .58 .35 .99 .032 .76 .44 2.27 .33
Relapse 1.66 1.30 2.11 <.0001 2.54 1.83 3.51 <.0001
J. Koreth et al. / Biol Blood Marrow Transplant 20 (2014) 1516e1521 1521prophylaxis, with “hard” endpoints of relapse, NRM, and
survival, help minimize concerns to the extent possible.
Importantly, prior risk factors (eg, age, DRI, WBC risk score,
ALC) retained signiﬁcance in multivariable models, with
early donor chimerism proving a novel independent variable.
Transplantation variables (eg, transplantation year, condi-
tioning intensity, sirolimus use) did not affect the ﬁndings,
allaying some of the concerns regarding applicability of the
ﬁndings to other T cellereplete RIC regimens. Additionally, in
multivariable landmark analyses excluding patients with
early morphologic relapse within 30 days after chimerism
assessment, total donor cell chimerism retained indepen-
dent prognostic signiﬁcance: D30 was associated with PFS
(P¼ .019) and D100was associated with PFS and OS (P< .001,
P ¼ .024, respectively). Validation of our ﬁndings in other
datasets, however, remains important.
This study represents the largest systematic assessment
of the impact of early donor chimerism on long-term out-
comes. We document that early total donor chimerism
independently predicts long-term relapse and survival. We
also document that total donor cell chimerism is sufﬁcient
and assessing T subset chimerism is of no additional value to
predicting these endpoints. Based on these ﬁndings, pro-
spective interventions to enhance donor chimerism, reduce
relapse, and improve long-term survival should be consid-
ered early after T cellereplete RIC HSCT.
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